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Abstract
Background. Transcatheter aortic valve implantation
(TAVI) for high-risk and inoperable patients with severe
aortic stenosis is an emerging procedure in cardiovascular
medicine. Little is known of the impact of TAVI on renal
function.
Methods. We analysed retrospectively renal baseline char-
acteristics and outcome in 58 patients including 2 patients
on chronic haemodialysis undergoing TAVI at our institu-
tion. Acute kidney injury (AKI) was defined according to
the RIFLE classification.
Results. Fifty-eight patients with severe symptomatic aor-
tic stenosis not considered suitable for conventional surgical
valve replacement with a mean age of 83 ± 5 years under-
went TAVI. Two patients died during transfemoral valve
implantation and two patients in the first month after TAVI
resulting in a 30-day mortality of 6.9%. Vascular access
was transfemoral in 46 patients and transapical in 12. Es-
timated glomerular filtration rate (eGFR) increased in 30
patients (56%). Fifteen patients (28%) developed AKI, of
which four patients had to be dialyzed temporarily and one
remained on chronic renal replacement therapy. Risk fac-
tors for AKI comprised, among others, transapical access,
number of blood transfusions, postinterventional thrombo-
cytopaenia and severe inflammatory response syndrome
(SIRS).
Conclusions. TAVI is feasible in patients with a high bur-
den of comorbidities and in patients with pre-existing end-
stage renal disease who would be otherwise not considered
as candidates for conventional aortic valve replacement.
Although GFR improved in more than half of the patients,
this benefit was associated with a risk of postinterventional
AKI. Future investigations should define preventive mea-
sures of peri-procedural kidney injury.
Keywords: acute kidney injury; severe inflammatory response
syndrome; transcatheter aortic valve implantation
Introduction
Despite the proven benefit of surgical valve replacement,
almost one-third of patients with severe valvular heart dis-
ease (VHD) do not undergo intervention because of end-
stage disease, advanced age and multiple comorbidities,
including chronic kidney disease (CKD) [1]. Transcatheter
aortic valve implantation (TAVI) for high-risk patients has
emerged as a new therapeutic option, first reported in 2002
by Cribier [2]. Meanwhile, more than 2000 TAVI have been
performed using a transfemoral or a transapical approach
in patients with an estimated excessive perioperative risk
or in those with contraindications for conventional surgical
aortic valve replacement [3–10]. Information about the im-
pact of TAVI on renal function is scarce. Two studies have
reported the necessity of renal replacement therapy (RRT)
as a postoperative outcome in a total of 9 from 69 patients
C© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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being treated with haemofiltration [11,12]. In the study of
Svensson, 15 out of 40 patients undergoing TAVI died. Six
of these patients had renal failure [6]. In all of these reports,
renal failure was not defined, pre-existing impaired renal
function was not specified and information about pre- and
postinterventional GFR in the remaining patients was miss-
ing. Thus, no systematic renal data in patients after TAVI
are available. We therefore analysed our cohort of TAVI
patients with respect to pre- and postinterventional renal
function and assessed risk factors for acute kidney injury
(AKI).
Subjects and methods
From August 2007 to September 2008, TAVI was performed in 58 pa-
tients with severe symptomatic aortic stenosis not considered suitable for
conventional surgical valve replacement (Table 1). The patients underwent
diagnostic left and right heart catheterization prior to TAVI. Procedures
were performed in the catheterization laboratory under local anaesthe-
sia. Vascular access was obtained through the common femoral artery or
through the ventricular apex using a 6 cm intercostal incision. In the case of
transfemoral access, either a self-expanding valve prosthesis (CoreValve
prosthesis, CoreValve Inc., Irvine, CA, USA) or a balloon-expandable
(Edwards Lifesciences, Irvine, CA, USA) valve prosthesis was used. In
the case of the transapical approach, balloon-expandable valve prosthe-
sis (Edwards Lifesciences, Irvine, CA) was employed. The procedures
were performed using high-quality fluoroscopic guidance with the use of
non-ionic contrast media. The primary endpoint of the present study was
renal outcome; secondary endpoints included 30-day mortality. Medical
records were reviewed by F.A., an investigator independent of the cardi-
ology and cardiovascular surgery team, for procedural success, mortal-
ity, hospitalization time, RRT, renal function, comorbidities, medication
and routine laboratory investigations. Estimated glomerular filtration rate
(eGFR) was calculated with the simplified Modification of Diet in Re-
nal Disease (MDRD) formula. Urine analysis was performed on the day
of admission with Combur10 Test R©. AKI was defined according to RI-
FLE classification [13]. Due to incomplete data of urinary output, we
did not include this variable for the purpose of classification. Creatinine
concentrations before TAVI were available in all patients. Daily creati-
nine measurements were available on 5.3 ± 1.6 days during the 7 day
interval after TAVI. Proteinuria was defined as a protein concentration
>15 mg/dl in random urine samples. The need for dialysis was pre-
dicted according to the bedside risk algorithm of Mehta [14]. During
the first 7 days after TAVI, blood count and C-reactive protein (CRP) were
recorded. Thrombocytopaenia was defined as a platelet count <140 ×
109/l. Leucocyte counts <4.0 and >12 were considered pathologic and
possibly SIRS related.
Statistical analysis was performed with GraphPadPrism version 5.01
and SAS 9.2 for Windows (SAS Institute Inc., Cary, NC, USA); the Mann–
Whitney U-test was applied for non-parametric data to compare groups;
the chi-square analysis and Fischer’s exact tests were considered for dis-
crete data. Spearman’s correlation coefficient was used to establish associ-
ations. Univariate and multivariate logistic regressions were done using the
SAS logistic procedure. Stepwise selection was used for model selection.
Results
TAVI was performed in 58 patients with severe symp-
tomatic aortic stenosis not considered suitable for con-
ventional surgical valve replacement (Table 1). Successful
implantation of the device was achieved in 56 of 58 pa-
tients (97%). The mean aortic valve gradient declined from
51.2 ± 17 mmHg to 9.4 ± 4.9 mmHg. One patient required
extracorporeal cardiac support during the intervention. Two
patients died during the intervention. Another two patients
died in the first 30 days after TAVI. Thirty-day mortality
was 6.9% in all patients and 50% in patients with postoper-
Table 1. Baseline characteristics of the patients before transaortic valve
implantation
Patients All With AKI Without AKI
Number of patients 58 15 39
Age (years) (mean ± SD) 83 ± 5 83 ± 6 83 ± 5
Female sex, n (%) 34 (59) 8 (53) 23 (59)
Hypertension, n (%) 49 (83) 14 (93) 31 (79)
Diabetes mellitus, n (%) 12 (21) 5 (33) 5 (13)
Coronary artery disease,
n (%)
30 (52) 9 (60) 20 (51)
Peripheral vascular
disease, n (%)
21 (36) 8 (53) 11 (28)
NYHA class I+II, n (%) 12 (21) 2 (13) 9 (23)
NYHA class III and IV,
n (%)
46 (79) 13 (87) 30 (77)
Left ventricular EF%,
(mean ± SD)
49 ± 15 49 ± 17 49 ± 15
Logistic EuroSCORE%,
(mean ± SD)a
27 ± 16 25 ±10 27 ± 17
Creatinine (µmol/l)
(mean ± SD)
123 ± 88 123 ± 72 104 ± 42
eGFR, ml/min/1.73 m2
(mean ± SD)
55 ± 26 57 ± 33 58 ± 22
eGFR < 60 ml/min/
1.73 m2, n (%)
35 (60) 9 (60) 22 (56)
ESRD, before TAVI,
n (%)
2 (0.04) 0 0
Proteinuria, >150 mg/l,
n (%)
11 (19) 4 (27) 7 (18)
Predicted need for
dialysis (%) (mean ±
SD)b
3.1 ± 4.0 4.7 ± 5.7∗ 2.5 ± 3.2
A total of 58 patients were analysed. Two patients died during the procedure
and two were already on chronic haemodialysis before the intervention.
Thus, 54 patients were considered for the analysis of the impact of TAVI
on renal function.
∗P < 0.05 in patients with AKI versus without AKI.
aLogistic EuroSCORE indicates the predicted mortality in case of cardiac
surgery [25].
bAnalysis without the two patients on dialysis.
ative need for dialysis. The preprocedural renal function in
the four patients who died in the first month was not lower
than in those who did not die.
Two patients were on chronic haemodialysis prior to
TAVI and survived the intervention without adverse events.
Accordingly, 54 patients were available for the analysis of
the impact of TAVI on renal function. From admission to
Day 7 after TAVI, eGFR increased in 30 patients, declined in
21 and remained unchanged in 3 patients (Figure 1). Follow-
ing TAVI, 15 of 54 patients (28%) developed AKI according
to the RIFLE criteria. The baseline characteristics of the
patients with and without AKI were comparable except for
a significantly higher predicted probability of postoperative
need for dialysis [14] (Table 1). According to the RIFLE
criteria, seven patients were at risk (13.0%), four patients
had injury (7.4%) and four showed failure (7.4%). The time
course of renal function after TAVI in patients with AKI is
shown in Figure 2. Three patients with failure and one with
injury (hypervolaemia) had to undergo dialysis. One of
these four patients remained on chronic haemodialysis ther-
apy and two died. The valve was replaced more frequently
by the transapical approach in patients who subsequently
developed AKI (Table 2). As compared with patients
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Fig. 1. Percentage change of renal function (eGFR) from the day before
the intervention and Day 7 after TAVI, or at discharge if earlier, in all 54
patients analysed for the impact of TAVI on renal function. GFR increased
in 30 patients, declined in 21 and remained unchanged in 3 patients. •
indicates the patients with dialysis treatment after TAVI.
without AKI, patients with AKI had a higher maximal
postinterventional serum creatinine concentration, lower
minimal eGFR and a more pronounced decline in eGFR.
Patients with AKI had a lower haemoglobin concentration,
received a higher number of blood cell transfusion units,
encountered more frequently thrombocytopaenia postpro-
Fig. 2. Time course of renal function as assessed by serum creatinine
concentration after TAVI in the 15 patients with AKI. indicates days on
which haemodialysis was performed; † indicates patients who died during
hospitalization; ∗patient remained on chronic haemodialysis after TAVI.
cedurally, had a higher incidence of pathological leucocyte
count compatible with SIRS and an increased length of
hospital stay (Table 2). Volume of contrast media used
(242 ± 101 ml versus 262 ± 104 ml), procedural success
(100% versus 100%), preinterventional (45 ± 16 mmHg
versus 52 ± 16 mmHg) and postinterventional aortic valve
gradients (9.7 ± 5.7 mmHg versus 9.4 ± 4.8 mmHg),
maximal postinterventional CRP concentrations (126 ± 77
mg/l versus 101 ± 66 mg/l) and 30-day mortality (13.3%
versus 0%) were not statistically significantly different in
patients with AKI than in those without it.
Univariate logistic regression analysis revealed a possi-
ble association of AKI with the apical versus transfemoral
approach (P< 0.003), thrombopaenia (P< 0.02), adminis-
tered blood cell transfusion units (0 versus 1 to 2 versus >3,
P < 0.02), pathological leucocyte count (P < 0.002) and
CRP concentration on Day 1 after TAVI (P < 0.06). The
small number of studied patients limited the possibilities
for extensive multivariate regression analysis. Neverthe-
less, combining all the above-mentioned variables into a
multivariate logistic regression model and using stepwise
selection revealed that AKI was definitively related to the
apical approach (P < 0.03), thrombopaenia (P < 0.03) and
pathological leucocyte count (P< 0.01). A significant cor-
relation was found between the minimal postinterventional
thrombocyte count and change in eGFR from Day 2 com-
pared to baseline (r = 0.37, P = 0.0079).
Discussion
TAVI is a new treatment option for patients with severe
aortic stenosis at an increased risk for conventional surgery
[3–9]. In the present study, we analysed renal outcome in
54 high-risk patients undergoing TAVI at a single centre.
Two patients on chronic haemodialysis were also followed
up. Both patients were successfully treated. Based on the
available literature, a total of three dialysis patients have
previously been reported treated with TAVI; the survival
Table 2. Outcome after transcatheter valve replacement
Patients All With AKI Without AKI P-valuea
Number of patients 58 15 39
Renal function
Maximal serum creatinine (µmol/l) (mean ± SD) 163 ± 130 239 ± 143 111 ± 48 0.0003
Minimal GFR, ml/min/1.73 m2 (mean ± SD) 46 ± 24 30 ± 22 54 ± 21 0.001
Decrease in GFR (%) (mean ± SD) 18 ± 22 49 ± 14 6 ± 8 <0.0001
Access
Transfemoral, n (%) 46 (79) 8 (53) 36 (92) 0.003
Transapical, n (%) 12 (21) 7 (47) 3 (8) 0.003
Minimal haemoglobin (mg/dl) (mean ± SD) 93 ± 13 88 ± 9 96 ± 14 0.02
Transfusion units, n (mean ± SD) 2.1 ± 3.9 3.7 ± 4.2 1.7 ± 3.9 0.007
Minimal thrombocyte count, 109/l (mean ± SD) 139 ± 60 114 ± 30 150 ± 67 0.04
Thrombocytopaenia, n (%) 34 (59) 13 (87) 19 (49) 0.01
Pathological leucocyte count, n (%) 23 (41) 10 (67) 11(28) 0.01
Days of hospitalization, median (range) 11 (5–50) 18 (10–50) 11 (5–32) 0.0003
A total of 58 patients were analysed. Two patients died during TAVI and two were already on chronic haemodialysis before the intervention. Thus, 54
patients were considered for the analysis of the impact of TAVI on renal function.
aP AKI versus without AKI.
bLeucocyte count >12 G/l and <4 G/l were considered pathologic.
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rate could not be derived from the publications [11,12].
Given the limited number of dialysis patients undergoing
treatment with TAVI, the utility of TAVI as a treatment op-
tion has to be determined in a prospective study in dialysis
patients. Severe aortic stenosis with left ventricular failure
is one mechanism responsible for an impaired glomerular
filtration rate. Unsurprisingly, eGFR was higher in more
than one-half of the patients 7 days after the procedure, and
TAVI has to be considered as a useful therapeutic option
to improve renal function in this patient population. Con-
versely, TAVI may impair renal function, either transiently
or definitely, in some patients. About one-fourth of our pa-
tients developed AKI and 7.4% required RRT. In compari-
son, the need for RRT in surgical aortic valve replacement
is estimated to be 4.5% [15]. This population is not com-
parable with our patients as comorbidities and pre-existing
CKD were more frequently observed in our population.
As compared with the transfemoral technique, the
transapical approach was more often associated with AKI.
Given the small number of patients, we can only specu-
late on the mechanisms for this difference. The most likely
explanation is more prominent generalized arteriosclerosis
and more advanced disease in transapical patients, since
tortuous iliac vessels not allowing safe peripheral arterial
catheterization, excessive calcification of the ascending
aorta or the aortic arch was the reason for choosing the
transapical approach.
Platelets decreased significantly in all patients after
TAVI. The platelet count correlated with the decrease in
GFR, and minimal postprocedural platelet counts were sig-
nificantly lower in patients with AKI than without. More-
over, thrombocytopaenia was an independent risk factor
for AKI in multivariate analysis. Thrombocytopaenia is a
well-known feature after cardiovascular surgery, mainly at-
tributed to mechanical destruction of platelets, haemodi-
lution in the extracorporeal circuit (ECC), drugs and in-
travascular coagulation [16]. The incidence of acquired
thrombocytopaenia in our patients was high (59%) and
in line with the high incidence of thrombocytopaenia ob-
served in a group of 25 patients undergoing percutaneous
CoreValve implantation with extracorporeal percutaneous
femoro-femoral bypass [9]. In the latter group, one patient
died of fatal disseminated intravascular coagulation. Our
patients, however, had no cardiopulmonary bypass support
except for one. Intravascular coagulation is an established
mechanism for AKI. Thus, it is a potential mechanism ac-
counting for AKI in the present cohort probably induced by
the valve itself. We cannot rule out that the lower thrombo-
cyte counts in AKI patients are caused by the larger peripro-
cedural blood loss, as AKI patients had a higher amount of
transfusion units. Blood transfusion is a known risk fac-
tor for AKI [17,18]. In the present study, however, neither
minimal postinterventional haemoglobin nor the amount
of transfused units were related to AKI in the multivariate
analysis. Thus, we do not consider blood loss to be the main
cause of AKI in our patients.
Another potential mechanism for AKI is SIRS. Following
TAVI, some patients had fever without clear focus and all
patients showed an increase in CRP concentrations (mean ±
SD CRP concentration before TAVI 12 ± 18 mg/dl versus
after TAVI 108 ± 69 mg/dl, P < 0.0001). This increase
in CRP was higher than that reported after percutaneous
coronary intervention (∼2 mg/dl) and surgical valve re-
placement (∼66 mg/dl) [19–21]. Moreover, a pathological
leucocyte count as seen in SIRS was an independent risk
factor for AKI in multivariate analysis. The mechanisms
for these observations are not known and therefore must be
investigated in the future.
Patients were not evaluated prospectively for typical clin-
ical findings of atheroembolism and eosinophilia after the
intervention was assessed only in some of the patients.
Thus, we can only speculate whether atheroembolism was
another cause of AKI in some patients.
The mechanisms of AKI following TAVI deserve con-
sideration for future preventive strategies. First, contrast
media with the potential to induce acute tubular necrosis
should be used at low doses. Intravenous hydration, an es-
tablished preventive measure for contrast media nephrotox-
icity, is probably not applicable given the restricted cardiac
performance of these patients. Although controversial, im-
mediate dialysis after the interventions might be an option
for reducing contrast media toxicity [22–24]. Second, the
mechanism of SIRS in this subset of patients is unclear and
should be elucidated. Third, the requirement for blood cell
transfusions has to be diminished.
In conclusion, the present observation demonstrates that
transcatheter aortic valve implantation is feasible in patients
not qualifying for open heart surgery, including patients on
haemodialysis, with a high rate of procedural success and a
30-day mortality lower (7%) than predicted by risk scores
(27%). Improvement of eGFR was seen in the majority
of patients. The incidence of AKI (27%) was associated
with the transapical approach, requirement of blood trans-
fusions, thrombocytopaenia, pathological leucocyte counts
and SIRS. Future investigations have to focus on the pre-
ventive mechanisms for AKI in patients who should receive
this promising alternative and less invasive valve replace-
ment procedure.
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Abstract
Background. Increasing the dose of renal replacement ther-
apy has been shown to improve survival in critically ill
patients with acute kidney injury (AKI) in several smaller
European trials. However, a very recent large multicentre
trial in the USA could not detect an effect of dose of renal
replacement therapy on mortality. Based on those studies,
it is not known whether a further increase in dialysis dose
above and beyond the currently employed doses would im-
prove survival in patients with AKI. We therefore aimed to
C© The Author [2009]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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